pre-IPO PHARMA

COMPANY OVERVIEW

Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. Jasper Therapeutics’ lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.


LOCATION

  • Palo Alto, CA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://jaspertherapeutics.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    abingworth alexandria-venture-investments qiming-venture-partners surveyor-capital


    PRESS RELEASES


    Sep 24, 2021

    Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy


    Sep 20, 2021

    Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members


    Sep 8, 2021

    Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes


    Jun 14, 2021

    Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant


    Jun 1, 2021

    Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting


    For More Press Releases


    Google Analytics Alternative